SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout
February 25, 2021 13:00 ET | Source: Rigrodsky Law, P.A Rigrodsky Law, P.A Wilmington, Delaware, UNITED STATES
WILMINGTON, Del., Feb. 25, 2021 (GLOBE NEWSWIRE) Rigrodsky Law, P.A. announces that it is investigating Pandion Therapeutics, Inc. (“Pandion”) (NASDAQ GS: PAND) regarding possible breaches of fiduciary duties and other violations of law related to Forterra’s agreement to be acquired by Merck & Co., Inc. (“Merck”) (NYSE: MRK). Under the terms of the agreement, Pandion’s shareholders will receive $60.00 in cash per share.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-pandion-inc.
Analyzing The Price Action In Pandion Therapeutics Stock Today benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Merck To Acquire Pandion Therapeutics finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
News Category Global Banking & Finance Reviews
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
-Phase 1a trial achieved primary objective of safety and tolerability
-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases
-PT101 maintained selectivity for regulatory T cells at all doses tested
-Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021
-Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET
NodThera Appoints Chief Medical Officer and Chief Financial Officer marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.